• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6872.TWO
Share

NaviFUS Corp. Stocks

NT$ 19.35Last Updated 19.10.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

NT$ 44.18M

NT$ 19.35
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

NaviFUS Corporation operates within the medical device sector, specializing in the development and commercialization of advanced focused ultrasound (FUS) technologies tailored for neurological applications. The company's primary offering is NaviFUS, a sophisticated transcranial FUS system precisely guided by neuronavigation. This innovative system is engineered to deliver concentrated energy to deep brain regions, supporting a range of clinical interventions such as enhanced drug delivery, neuromodulation, and immuno-stimulation. Additionally, NaviFUS Corp. provides NAVIRFA, a sophisticated navigation system that utilizes optical three-dimensional surgical tracking technology. Its purpose is to accurately monitor the exact placement of needle tips during various ultrasonic interventional procedures. Founded in 2015, the company's headquarters are located in Taipei, Taiwan.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

20.10.2026 01:27

A Breather After the Plunge: Nasdaq Rebounded 1.2% as Demand for AI Stocks Returned

20.10.2026 00:18

One of Intel’s last bears gives up negative rating amid stock’s plunge

19.10.2026 22:51

Neobank Plata, founded by former Tinkoff execs, achieves $1 bln in annualized revenue

19.10.2026 22:31

Morgan Stanley raises Amazon target price, sees 40% upside on cloud growth, AI agents

19.10.2026 21:53

Apple sets October 28 event to unveil first touchscreen MacBook, Bloomberg reports

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026